skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

The future role of personalized medicine in the treatment of glioblastoma multiforme

Review

(2042) Views  (1000) Full article downloads

Authors: Jing Li, Chunhui Di, Austin K Mattox, et al

Published Date August 2010 Volume 2010:3 Pages 111 - 127
DOI: http://dx.doi.org/10.2147/PGPM.S6852

Jing Li1,2, Chunhui Di1,2, Austin K Mattox1,2, Linda Wu1,2, D Cory Adamson1,2,3,4

1Preston Robert Tisch Brain Tumor Center, Duke Medical Center, Durham, North Carolina, USA; 2Department of Surgery (Neurosurgery), Duke Medical Center, Durham, North Carolina, USA; 3Department of Neurobiology, Duke Medical Center, Durham, North Carolina, USA; 4Neurosurgery Section, Durham VA Medical Center, Durham, North Carolina, USA

Abstract: Glioblastoma multiforme (GBM) remains one of the most malignant primary central nervous system tumors. Personalized therapeutic approaches have not become standard of care for GBM, but science is fast approaching this goal. GBM’s heterogeneous genomic landscape and resistance to radiotherapy and chemotherapy make this tumor one of the most challenging to treat. Recent advances in genome-wide studies and genetic profiling show that there is unlikely to be a single genetic or cellular event that can be effectively targeted in all patients. Instead, future therapies will likely require personalization for each patient’s tumor genotype or proteomic profile. Over the past year, many investigations specifically focused simultaneously on strategies to target oncogenic pathways, angiogenesis, tumor immunology, epigenomic events, glioma stem cells (GSCs), and the highly migratory glioma cell population. Combination therapy targeting multiple pathways is becoming a fast growing area of research, and many studies put special attention on small molecule inhibitors. Because GBM is a highly vascular tumor, therapy that directs monoclonal antibodies or small molecule tyrosine kinase inhibitors toward angiogenic factors is also an area of focus for the development of new therapies. Passive, active, and adoptive immunotherapies have been explored by many studies recently, and epigenetic regulation of gene expression with microRNAs is also becoming an important area of study. GSCs can be useful targets to stop tumor recurrence and proliferation, and recent research has found key molecules that regulate GBM cell migration that can be targeted by therapy. Current standard of care for GBM remains nonspecific; however, pharmacogenomic studies are underway to pave the way for patient-specific therapies that are based on the unique aberrant pathways in individual patients. In conclusion, recent studies in GBM have found many diverse molecular targets possible for therapy. The next obstacle in treating this fatal tumor is ascertaining which molecules in each patient should be targeted and how best to target them, so that we can move our current nonspecific therapies toward the realm of personalized medicine.

Keywords: GBM, oncogenomics, genetics, signaling cascades, pharmacogenomics







Readers of this article also read:

Integrating epigenomics into pharmacogenomic studies
The genetic overlap of attention deficit hyperactivity disorder and autistic spectrum disorder
The implications of pharmacogenomics in the treatment of HIV-1-infected patients of African descent
Pharmacogenomics in osteoporosis: Steps toward personalized medicine
Gene polymorphisms in association with self-reported stroke in US adults
The molecular mechanisms and pharmacotherapy of ATP-sensitive potassium channel gene mutations underlying neonatal diabetes
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross
Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy
The role of genetics in pre-eclampsia and potential pharmacogenomic interventions